Long-Term Retention, Efficacy, and Safety of Secukinumab in Moderate to Severe Plaque Psoriasis: Findings from a 5-Year SERENA Study

1

The SERENA study evaluated the long-term retention, efficacy, and safety of secukinumab in moderate to severe plaque psoriasis over five years.
2

Secukinumab demonstrated high treatment retention and sustained effectiveness, significantly improving skin clearance and quality of life for patients.
3

Early intervention with secukinumab is crucial for achieving better long-term outcomes in managing plaque psoriasis.
4

The study involved approximately 2700 patients across 438 sites in Europe and Israel, providing robust real-world evidence.
5

Secukinumab maintained a consistent safety profile, with no new safety concerns identified during the five-year follow-up.

Dermatology And Therapy (Springer)

by Matthias Augustin, Paul-Gunther Sator, Ralph von Kiedrowski, Dimitris Rigopoulos, Marco Romanelli, Pierre-Dominique Ghislain, Tiago Torres, Dimitrios Ioannides, Cynthia Vizcaya, Andreas Clemens, Weibin Bao, Christelle C. Pieterse, Barbara Schulz, Piotr Jagiello, Curdin Conrad
April 2, 2026

1